RxDoctor Payments Data

Nina Leonard

Nurse Practitioner · Saint Marys, GANPI 1679877526

Payments from drug & device makers

$5,311in general payments, 2019–2025

Across 327 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Lundbeck LLC$494
  • Axsome Therapeutics, Inc.$311
  • Tris Pharma Inc$307
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$298
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,311 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$41,054
Medicare patients
71
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl155$217,587
Abilify MaintenaAripiprazole26$69,393
TrintellixVortioxetine Hydrobromide90$56,679
Invega SustennaPaliperidone Palmitate13$34,877
BelsomraSuvorexant14$6,354
DayvigoLemborexant19$6,223
Venlafaxine Hcl ErVenlafaxine Hcl49$3,324
Paliperidone ErPaliperidone20$3,048
Buspirone Hcl200$2,994
Quetiapine Fumarate95$2,459
Chlorpromazine Hcl15$2,337
Clozapine17$2,181
Lamotrigine188$2,168
Duloxetine Hcl79$1,987
Trazodone Hcl171$1,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,278$217,587155 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$268$69,39326 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,026$56,67990 claims
Johnson & JohnsonInvega Sustenna$35$34,87713 claims
Almatica Pharma LLCSertraline Hcl$227$49255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Saint Marys

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →